© University Hospital LMU München and University Hospital Klinikum rechts der Isar
Effective Translational Oncology needs to combine the increasing insights into the pathobiology of malignant diseases with the rising options of therapy. Here, the DKTK partner site München has its main focus on detecting and unravelling common pathways for cancer therapy (COMPACT) with the following concepts:
- A unique bench to bedside and beside to bench approach based on in vitro and in vivo models including mouse models and primary patient samples collected within national and international multicenter studies.
- Concentration on distinct tumor entities such as acute leukemia and malignant lymphoma, gastrointestinal cancer including colorectal and pancreatic cancers as well as neuro-oncology.
- Broad spectrum of model systems and research facilities including next-generation genetic technologies (e.g. transposon tools, CRISPR/Cas9, large animal models, dual- and triple-recombinase systems), further "omics" profiling techniques (Genomics and Proteomics platform) as well as forward genetic and synthetic lethality screens.
Mandatory sampling of patients’ material within the respective clinical trials and an informative patient registry for cases with specific and/or unusual features allow to identify well defined patient subgroups. These subgroups are analyzed for tumor driving pathway alterations by respective screening techniques and in preclinical models, the latter also serving for the testing of new agents. Particularly subsequent cross-tumor analyses are supported which may not only result in a new categorization of tumors according to pathway alterations rather than histology but also in new strategies of exploring new agents across tumors with common pathway alterations in the preclinical as well as in the clinical setting.
The partner site is in close cooperation with established (inter-)national study groups such as the German Low Grade Lymphoma Study Group (GLSG), the European Mantle Cell Lymphoma Network, the German AML Cooperative Group (AMLCG) and the AIO Gastrointestinal Cancer Working Group. In addition, there is a close connection to other research networks such as SFB 1371, SFB 1335, SFB 1321, SFB 1243, SFB 824, FOR 2033, Helmholtz Alliance PCCC, EU FP7 and several ERC, Max Eder and Emmy Noether fellowships.